Business Case

Developed a value proposition for an EGFR-targeting biologic intended to be marked by a large international pharmaceutical company to present to IMSS in Mexico

A large, international pharmaceutical company was looking to take their EGFR-targeting biologic to the Mexican market and sought assistance developing a robust value proposition. LSC collaborated to craft a robust value proposition, assessing its clinical, economic, and social impact in comparison to alternative treatments offered by IMSS. LSC’s comprehensive analysis not only highlighted the therapy’s benefits, but also provided recommendations to IMSS for optimal resource management, solidifying our client’s position for a favorable review.